Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer with BRAF-mutations: a retrospective study
Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.
Authors
- Xu Sun (ORCID: https://orcid.org/0009-0005-6435-6481)
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- American Journal of Cancer Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/mvnl2093
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00